StreetInsider.com News Articles

Inhibikase Therapeutics (IKT) Reiterated at Overweight by Cantor Fitzgerald

Tue, 19 May 2026 07:14:44 -0400

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $4.00 price target on Inhibikase Therapeutics Inc (NASDAQ: IKT).

The analyst commented, "We had a very productive lunch with the IKT management team today at ATS 2026. The overall tone around IKT-001 was very confident, and the core thesis is that imatinib works in PAH – it’s just about solving for the tolerability and keeping patients on therapy long enough to realize the anti-proliferative benefit. The IKT pitch is that the combinations of 1) a prodrug approach, 2) gradual dose titration, and 3) improved/modernized patient management, can fundamentally change the risk/benefit

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: ADAR1 Capital Management, LLC

Fri, 15 May 2026 20:13:00 -0400

si-local-file:///var/storage/secattach/20260515/26508421.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: ADAR1 Capital Management, LLC

Fri, 15 May 2026 20:13:00 -0400

si-local-file:///var/storage/secattach/20260515/26508421.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Trails Edge Capital Partners, LP

Fri, 15 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26505879.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Trails Edge Capital Partners, LP

Fri, 15 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26505879.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Commodore Capital LP

Fri, 15 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260515/26505595.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Commodore Capital LP

Fri, 15 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260515/26505595.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504585.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504585.html

Inhibikase Therapeutics (IKT) Misses Q1 EPS by 10c

Tue, 12 May 2026 17:49:00 -0400

Inhibikase Therapeutics (NASDAQ: IKT) reported Q1 EPS of ($0.10).

For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.

Form 10-Q Inhibikase Therapeutics, For: Mar 31

Tue, 12 May 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260512/26478740.html

Form 10-Q Inhibikase Therapeutics, For: Mar 31

Tue, 12 May 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260512/26478740.html

Form 8-K Inhibikase Therapeutics, For: May 12

Tue, 12 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260512/26478588.html

Form 8-K Inhibikase Therapeutics, For: May 12

Tue, 12 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260512/26478588.html

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Tue, 12 May 2026 16:01:00 -0400

WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2026, and highlighted recent developments.

“We were excited to enroll the first patient in our registrational IMPROVE-PAH study last month, and are very pleased with our early progress obtaining country regulatory approvals to support initiation of clinical sites, including being one of the first companies to successfully take advantage of the new European Medicines Agency FAST-EU (Facilitating and

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Tue, 12 May 2026 16:01:00 -0400

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Tue, 12 May 2026 16:01:00 -0400

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Tue, 12 May 2026 16:01:00 -0400

Form ARS Inhibikase Therapeutics, For: Dec 31

Thu, 30 Apr 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260430/26408378.html

Form ARS Inhibikase Therapeutics, For: Dec 31

Thu, 30 Apr 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260430/26408378.html

Form DEFA14A Inhibikase Therapeutics,

Thu, 30 Apr 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260430/26408151.html

Form DEFA14A Inhibikase Therapeutics,

Thu, 30 Apr 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260430/26408151.html

Form DEF 14A Inhibikase Therapeutics, For: Jun 26

Thu, 30 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260430/26407761.html

Form DEF 14A Inhibikase Therapeutics, For: Jun 26

Thu, 30 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260430/26407761.html

Form PRE 14A Inhibikase Therapeutics, For: Jun 26

Mon, 20 Apr 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260420/26336991.html